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Abstract
The Gi-coupled A3 adenosine receptor (A3AR) mediates anti-inflammatory, anticancer and anti-
ischemic protective effects. The receptor is overexpressed in inflammatory and cancer cells, while
low expression is found in normal cells, rendering the A3AR as a potential therapeutic target.
Highly selective A3AR agonists have been synthesized and molecular recognition in the binding
site has been characterized. The present review summarizes preclinical and clinical human studies
demonstrating that A3AR agonists induce specific anti-inflammatory and anticancer effects via a
molecular mechanism that entails modulation of the Wnt and the NF-κB signal transduction
pathways. Currently, A3AR agonists are being developed for the treatment of inflammatory
diseases including rheumatoid arthritis and psoriasis; ophthalmic diseases such as dry eye
syndrome and glaucoma; liver diseases such as hepatocellular carcinoma and hepatitis.
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I. Introduction
The A3AR is a subtype of the adenosine receptor (AR) family, which additionally includes
the A1, A2A, and A2B receptors [1,2]; each is encoded by a separate gene and has different
physiological roles. The Gi-coupled A3AR is less widely distributed than other AR subtypes
with expression in humans in lung, liver, brain, aorta, testis and heart. The utilization of the
A3AR as a therapeutic target and a biological predictive marker is based on two major
findings: (a) A3AR is overexpressed in cancer and inflammatory cells, while low expression
is found in normal cells [3–5]. The high receptor expression is also found in peripheral
blood mononuclear cells (PBMCs) of patients with cancer or inflammatory diseases [5,6].
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(b) Highly selective A3AR agonists have been synthesized and induce specific anti-
inflammatory and anticancer effects via a molecular mechanism that entails modulation of
the Wnt and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)
signal transduction pathways [6–8] (Figure 1). A protective effect of the agonists on normal
cells was recorded as well, suggesting that this unique differential effect of the agonists will
contribute to a safety profile of these drug candidates in both pre-clinical and clinical
studies. Currently, A3AR agonists are being developed for the treatment of inflammatory,
ophthalmic and liver diseases and demonstrate excellent safety and efficacy in Phase 2
clinical studies.
II. A3AR Agonists
The human A3AR was cloned in 1993 [1] and soon thereafter found to have
cerebroprotective and cardioprotective properties [9, 10]. Like other G protein-coupled
receptors (GPCRs), it is also known to affect G protein-independent signaling, such as
translocation of arrestins, leading to rapid desensitization of the A3AR in vitro (typically
~20 min in the presence of agonist) [11,12]. Highly selective A3AR agonists have been
synthesized, and molecular recognition in the binding site has been characterized using site-
directed mutagenesis and molecular modeling. Typical A3AR agonists are adenosine
derivatives that contain 5‘-uronamide and N6-benzyl modifications leading to nanomolar
receptor affinity (compounds numbered in bold as shown in Figure 2) [13]. The prototypical
agonists IB-MECA 1 (N6-(3-iodobenzyl)-5‘-N-methylcarboxamidoadenosine, CF101) and
its 2-chloro analogue Cl-IB-MECA 2 (2-chloro-N6-(3-iodobenzyl)-5‘-N-
methylcarboxamidoadenosine, CF102) are 9-ribosides with A3AR selectivity. Other
selective A3 agonists include the 4‘-thio derivative 3, 3‘-amino-3‘-deoxy derivatives
CP-608,039 5 ((2S,3S,4R,5R)-3-amino-5-{6-[5-chloro-2-(3-methylisoxazol-5-
ylmethoxy)benzylamino]-purin-9-yl-l-4-hydroxytetrahydrofuran-2-carboxylic acid
methylamide) and its dichlorobenzyl analogue CP-532,903 4, which were originally
developed for cardioprotection, and the N6-methyl-2-ethynyl derivative 6 [9,14].
Introduction of a fused bicyclic ring in the rigid analogue MRS3558 7 ((1'R,2'R,3'S,4'R,
5'S)-4-{2-chloro-6-[(3-chlorophenylmethyl)amino]purin-9-yl}-1-(methylaminocarbonyl)-
bicyclo[3.1.0]hexane-2,3-diol) increased A3AR potency and selectivity, and identified the
North conformation of the ribose ring as the preferred conformation in receptor binding. 7
also shows a preference in potency for the cAMP pathway, in comparsion to arrestin
signaling [12]. Truncation of nucleosides at the 4‘-position reduces efficacy while retaining
affinity of binding to the A3AR. Thus, the methanocarba analogues MRS5147 9 ((1‘R,2‘R,
3‘S,4‘R,5‘S)-4‘-[2-chloro-6-(3-bromobenzylamino)-purine]-2‘,3‘-O-dihydroxybicyclo-
[3.1.0]hexane) and its 3-iodo analogue MRS5127 10 are low efficacy partial A3AR agonists,
that are selective in both human and rat [15]. Recently, macromolecular conjugates (e.g.
polyamidoamine dendrimers) of chemically functionalized AR agonists were introduced as
potent polyvalent activators of the receptors that are qualitatively different in
pharmacological characteristics in comparison to the monomeric agonists [16]. Several
A3AR PET ligands have been introduced for in vivo imaging: the antagonist
[18F]FE@SUPPY (5-(2-fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-
phenylpyridine-5-carboxylate [16], and a pair of nucleosides, e.g. low efficacy agonist
[76Br]MRS5147 9 and full agonist [76Br]MRS3581 8.
The selectivity of A3AR agonists differs between in vitro and in vivo models and between
species, although the sequence identity is high (84.4%) within the transmembrane region.
The characterization of a given nucleoside derivative as full or partial agonist is highly
dependent on the pharmacological system, such that 2 ranges from full agonist to low
efficacy partial agonist [17]. LUF6000 11 (N-(3,4-dichloro-phenyl)-2-cyclohexyl-1H-
imidazo[4,5-c]quinolin-4-amine) is a selective positive allosteric modulator of the human
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A3AR [18], increasing the maximal effect of inhibition of adenylate cyclase. Species-
dependence of the affinity and selectivity of A3AR antagonists should be carefully
considered in preclinical studies. Functional polymorphism of A3AR is known; a high-
transcript haplotype of the A3AR gene was associated with the development of cutaneous
hyper-reactivity to aspirin [19].
III. Differential expression of A3AR in pathological and normal cells
A3AR was found to be over-expressed in various neoplastic cells including leukemia,
lymphoma, astrocytoma, melanoma and pineal tumor cells, while low or almost no receptor
expression was found in normal cells [20–25]. Similar data were reported in studies the
receptor expression levels in tumor tissues derived from patients with colon, breast, small
cell lung, pancreatic and hepatocellular carcinomas, and melanoma in direct comparison
with adjacent normal tissues [3,4,6]. A direct correlation between A3AR expression levels
and disease progression was described in breast and colon cancer [3,4].
A similar pattern of receptor over-expression was described in inflammatory cells both in
experimental animal models and humans. The most studied inflammatory disease was
rheumatoid arthritis (RA) in which A3AR over-expression was detected in paw tissue,
draining lymph nodes and synovial cells of rats with adjuvant-induced arthritis and in
synovial cells from patients with RA [7]. Similar data were observed in colon tissues derived
from rats with colitis and in lungs upon inhalation of lipopolysaccharides (LPS) by mice
[26,27]. The receptor was also highly expressed in anterior segment tissues derived from
eyes with pseudoexfoliation syndrome in comparison to healthy subjects‘ eyes [28].
The high expression levels of A3AR seen in tumor and inflammatory cells were also found
in PBMCs derived from tumor-bearing animals and cancer patients [3,6]. Similarly, high
receptor expression levels were found in PBMCs derived from experimental animal models
of inflammation and from patients with autoimmune inflammatory diseases, such
rheumatoid arthritis, psoriasis and Crohn‘s disease [5,7,29].
These data suggest that A3AR expression levels in PBMCs mirror the receptor expression
levels in the remote tumor or inflammatory tissue, rendering the receptor a biological
marker. A3AR upregulation is attributed to factors including elevated adenosine and
cytokines, which are characteristic of the microenvironment of cancer and inflammatory
cells [29,30]. Under stressed metabolic conditions, extracellular adenosine of intracellular
origin accumulates in the surroundings [30,31]. Upon binding to cell surface receptors,
adenosine may induce, via an autocrine pathway, the expression of its own receptors. The
pro-inflammatory cytokine tumor necrosis factor-α (TNF-α), via binding to its cell surface
receptor, initiates downstream signaling to result in upregulation of protein kinase B (PKB)/
Akt, the inhibitor of nuclear factor of kappa light polypeptide gene enhancer in B-cells
(IκB), IκB kinase (IKK) and the transcription factor NF-κB [24,28]. The latter is known to
act as an A3AR transcription factor. Bioinformatic analyses revealed that besides NF-κB,
other transcription factors such as c-Rel, MyoD, c-fos, GR, CREB, AP-1, GATA-1, C/EBP,
c-Jun and PU.1 bind to the A3AR promoter region. It is well established that pro-
inflammatory cytokines regulate the cell expression levels of each of these transcription
factors, hence regulating A3AR expression levels [5]. Taken together, it seems that receptor
overexpression in tumors and inflammatory cells is a consequence and manifestation of the
disease state, rather than a causative factor.
Interestingly, in vivo pharmacological data revealed that chronic treatment with A3AR
agonist in various experimental animal models of cancer and inflammation did not
desensitize the receptor. This was evidenced by the downregulation of receptor expression
levels shortly after the last drug administration in a chronic mode of treatment [6,7,32]. In
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addition, 24 hours after the last agonist administration, A3AR protein expression level was
fully recovered to the control level, demonstrating that chronic treatment does not reduce the
receptor expression levels [32].
IV. In vivo pharmacological profile of A3AR agonists
A. Anticancer effect
In experimental animal models, A3AR agonists were efficacious in combating growth of
solid tumors, including melanoma, prostate, colon and hepatocellular carcinoma (Table 1).
The agonists showed efficacy upon chronic oral treatment, which was initiated after the
tumor was already established. Overall, the drugs were much more potent in the syngeneic
rather than in the xenograft models, pointing towards an immunological effect on top of the
direct anticancer effect. Supporting this notion are the findings showing that treatment with
2 increased interleukin-12 and potentiated NK activity in an animal model of melanoma
[33].
The direct mechanism of the anticancer effect of A3AR agonists entails modulation of the
NF-κB and the Wnt signaling pathways. In tumor lesions of A3AR agonist-treated animals,
the expression levels of PKB/Akt, IKK, NF-κB and TNF-α signaling proteins were
downregulated. The expression of glycogen synthase kinase 3 beta (GSK-3β) was
upregulated, while the expresssion of its downstream proteins, β-catenin, LEF1 and c-Myc,
was decreased, leading to inhibition of tumor cell growth [6,32,34]. Apoptosis, an additional
mechanism of action, was demonstrated in hepatocellular carcinoma tumors, and manifested
by increased expression of the pro-apoptotic proteins BAD, BAX and Caspase-3 upon
treatment with 2 [6]. These data prompted the selection of 2 as a drug candidate to be
developed as an anticancer agent for the treatment of hepatocellular carcinoma.
B. Anti-inflammatory effect
A3AR agonists possess a robust anti-inflammatory effect mediated by the inhibition of pro-
inflammatory cytokines [35–37]. 1, 2 and 3 exert anti-inflammatory effects in experimental
animal models of inflammatory bowel disease, systemic toxemia, pulmonary inflammation,
rheumatoid arthritis, osteoarthritis and liver inflammation (Table 2). The molecular
mechanism involved with the anti-inflammatory activity entails de-regulation of the NF-κB
signaling pathway, leading to inhibition of TNF-α, IL-6, IL-12, MIP-1α, MIP-2 and
RANKL, resulting in apoptosis of inflammatory cells [7,38].
C. Protective effects
Chemoprotective effect—Myelotoxicity is a severe and dose-limiting complication of
chemotherapy. Drug-induced myelosuppression is a major toxic factor that limits the
administration of larger, potentially more effective doses of chemotherapy.
A3AR agonists administered in combination with chemotherapeutic agents to tumor-bearing
mice prevented the myelotoxic effects of chemotherapy [39]. Coadministration of 1
prevented a decline in white blood cell (WBC) and neutrophil counts, resulting in full
recovery of myeloid system parameters. The A3AR agonist induced production of
granulocyte colony-stimulating factor (G-CSF), which stimulates myeloid progenitor cell
expansion in the bone marrow and increases the WBC and neutrophil counts in the
peripheral blood. The molecular mechanism underlying the events prior to G-CSF
production includes the upregulation of its transcription factor NF-κB and the upstream
kinases PI3K, PKB/Akt and IKK[39].
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In the cardiovascular system, A3AR agonists induce cardioprotection against chemotherapy-
induced damage. The anthracycline antibiotic doxorubicin (DOX) or adriamycin has been an
effective treatment for leukemias, lymphomas and solid tumors including breast cancer.
Acute cardiotoxicity of DOX develops during and shortly after the initiation of therapy.
However, chronic or late DOX-induced cardiotoxicity has a latency lasting for years prior to
the development of overt heart failure. Currently, only dexrazoxane, a free-radical
scavenger, shows promise as a cardioprotective agent during DOX treatment [40].
Developing new methods to reduce both acute and chronic cardiotoxicity should increase
the effectiveness of this anticancer therapy.
In this context, it is interesting to note that the A3 agonist 2 can protect against
mitochondrial damage and helps preserve ATP production in cultured rat cardiomyocytes.
Repeated i.v. injection of 2 prior to DOX administration in rats helped prevent left
ventricular wall thinning and dysfunction [41,42]. Whether continuous treatment with 2 can
delay or prevent the late DOX cardiotoxicity is unknown.
Cardioprotective anti-ischemic effect—A3AR agonists protect against myocardial
ischemia/reperfusion injury (I/R), which has been demonstrated using selective agonists and
A3AR-knockout mice, which are otherwise physiologically normal [43]. The
cardioprotective effect is evident in role of the A3AR in ischemic preconditioning and in
direct protection during ischemia. The A3AR may also be involved in mediating the post-
conditioning effect given its ability to reduce infarct size when it is administered during
reperfusion [9]. The A3AR has the lowest level of myocardial expression among the ARs, at
least for the murine heart. However, evidence has accumulated indicating that stimulation of
an endogenous cardiac A3AR, independent of circulating immune inflammatory cells or
resident mast cells, can result in cardioprotection [44]. An anti-inflammatory action of the
A3AR in vivo may also contribute importantly to the cardioprotective effect of A3 agonist.
Both a direct cardioprotective mechanism and an anti-inflammatory effect exerted at the
immune cell level in vivo may be important. Future studies are needed to address this
question. A cardioprotective role of the A3AR was also found in non-rodent mammals such
as rabbits and dogs [45,46].
Mediators for a direct myocardial protective effect include protein kinase C (PKC), KATP
channels, reactive oxygen species, connexin 43, mitochondrial permeability transition pore
(MPTP), and GSK-3β. Thus, a signaling cascade may begin with A3AR stimulation, PKC
activation, phosphorylation (and thus inactivation) of GSK-3β, leading to inhibition of
MPTP and reduced cardiac myocyte death [47]. The role of sarcolemmal vs. that of
mitochondrial KATP channels in mediating the A3 cardioprotection is not clear. There is
extensive evidence for a protective role of mitochondrial KATP (mito KATP) channel
including the recently elucidated function of connexin 43 in mediating mito KATP opening
by PKC. A recent study, however, showed that sarcolemmal KATP deletion abrogated the
preconditioning effect of A3AR agonist in murine heart [43]. Given the redundancy of
signaling pathways causing cardioprotection, it is possible that species differences exist in
the role of such signaling molecules. Genetic background could also modulate
cardioprotection not only in mice but also humans.
Protection of skeletal muscle—A3AR agonists attenuate skeletal muscle injury caused
by ischemia and reperfusion or eccentric exercise [48]. Skeletal muscle is susceptible to
various forms of injury, including ischemia, trauma, and physical exertion. Skeletal muscle
is one of the most vulnerable tissues in the extremities. Developing new methods designed
to provide cytoprotection to the skeletal muscle is thus important. Direct infusion of
adenosine can mimic the skeletal muscle protective effect of ischemic preconditioning in
extensor digitorum longus muscle before aorta occlusion in the rat as well as in the pig
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latissimus dorsi muscle flap model. A3AR agonist, when administered in vivo, signals
selectively via phospholipase PLCβ2/β3 to cause a reduction in skeletal muscle injury
sustained either during ischemia/reperfusion or eccentric exercise [48]. While A1 and
A2AARs can also mediate anti-ischemic protection in skeletal muscle, only the A3AR can
induce protection against both I/R and eccentric exercise injuries.
Given that activation of the A3AR has a known anti-inflammatory effect, it is possible that
skeletal muscle protective effect is mediated, at least, in part at an immune cell level. The
following lines of evidence support this hypothesis. First, activated mast cells and
neutrophils are important contributors of skeletal muscle ischemia/reperfusion damage.
Second, activation of the A3AR can block superoxide formation and chemotaxis of murine
bone marrow neutrophils [49].
Lung ischemia/reperfusion protection—A3AR agonist prevents lung injury following
ischemia/reperfusion in the cat. Compound 3 produced a sustained protection, which was
associated with suppressed p38 protein expression and downregulation of its
phosphorylation [50,51].
Neuroprotection—Evidence from diverse models suggests that neuroprotective effects
may be mediated by the A3AR, but differences between acute and chronic agonist
administration have been noted [10]. Ischemic brain injury in a model of forebrain ischemia
in gerbils is reduced upon chronic treatment with 1 [52]. A3AR agonist was found to prevent
the loss of retinal ganglion cells following activation of the P2×7 receptor in a rat
experimental model [53].
V. CF101 for the treatment of inflammatory and ophthalmic diseases
Based on the pre-clinical pharmacology data and encouraging safety data in Phase I studies
[54], the anti-inflammatory effect of 1 was tested in a set of three Phase II clinical studies
including rheumatoid arthritis (RA), psoriasis and dry eye syndrome (Table 3). Overall, the
data obtained from these clinical studies showed excellent safety profile and efficacy,
positioning 1 as a disease-modifying anti-inflammatory drug.
A. Rheumatoid Arthritis
A chronic, systemic inflammatory disorder attacking the joints resulting in inflammatory
synovitis that may progress to the destruction of articular cartilage and bone [55]. The
mechanisms responsible for causing joint damage and functional impairment in RA are
complicated and involve B cell or T cell products stimulating the release of TNF and other
pro-inflammatory cytokines, including interleukin-1, interleukin-6, and TNF-α and
degradative enzymes.
In a multi-center Phase II study, blinded to dose (0.1, 1.0, or 4.0 mg), the drug was
administered orally, twice daily for 12 weeks to patients with active RA. The primary
efficacy endpoint was an improvement of 20% or more according to the classification of RA
responses by the American College of Rheumatology (ACR) [55]. Compound 1 was found
to be safe and well tolerated, and the maximal responses were observed in patients treated
with a 1.0 mg dose. At 12 weeks, 55.6%, 33.3%, and 11.5% of the patients receiving 1.0 mg
1 achieved ACR20%, 50%, and 70% responses, respectively. In addition, a statistically
significant correlation between A3AR expression at baseline and patient response to 1 was
observed, rendering the A3AR as a biological predictive marker [56].
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B. Psoriasis
A chronic inflammatory skin disease characterized by epidermal hyper-proliferation and
immature differentiation resulting in multisystem pathology and a negative impact on the
quality of life of the patients [57]. Pro-inflammatory cytokines, such as INF-γ, TNF-α, IL-23
and Th17 are known to play a role in mediating the inflammation and epidermal alterations
in psoriasis [58].
The efficacy and safety of 1 were tested in a Phase II, multicenter, randomized, double
blind, dose-ranging, placebo-controlled study in patients with moderate-to-severe chronic
plaque-type psoriasis. Compound 1 (1, 2, or 4 mg) or placebo was administered orally twice
daily for 12 weeks. Overall, the drug was safe and well tolerated.
The maximal improvement in the mean change from baseline in the PASI (psoriasis area
and severity index) score vs. placebo and the highest percentage of patients who achieved
PGA (physician‘s global assessment) score of 0 or 1 were observed in the 2 mg 1-treated
group. The improvement was progressive and linear throughout the study period. Thus, 1
was safe and well tolerated.
C. Dry Eye Syndrome
An inflammatory condition of the eye that is caused by decreased tear production or
increased tear film evaporation. It is characterized by massive production of pro-
inflammatory cytokines. The dryness and the inflammation could result in eye damage
leading to impaired vision [59,60].
Anecdotal findings demonstrating that 1 improved indicators of dry eye syndrome in RA
patients led to a separate randomized, multi-center, doubled-masked, placebo-controlled,
parallel-group, Phase II clinical study of the safety and efficacy of 1 (1 mg) administered
orally daily for 12 weeks to patients with moderate-to-severe dry eye syndrome. Conpound
1 was safe and well tolerated and no serious adverse events were noted throughout the study.
Treatment with 1 resulted in a statistically significant improvement in the mean change from
baseline at week 12 of the clearance of corneal staining, tear break-up time and tear
meniscus height in the group treated with 1 vs. placebo. Compound 1 was well tolerated and
exhibited an excellent safety profile with no serious adverse events. Interestingly, a
statistically significant decrease from baseline was observed in the intraocular pressure of
the 1-treated patients in comparison to the placebo-treated group [61].
No serious adverse events in the RA, psoriasis or dry eye clinical studies were observed. The
profile of the adverse events was similar between the placebo and 1-treated groups.
VI. Conclusions
Based on the experimental animal data and human clinical study results presented in the
current review, A3AR is suggested as a specific and unique therapeutic target to combat
proliferative diseases including inflammation and cancer. The excellent safety profile of
A3AR agonists, currently tested in human clinical studies, is attributed to the different
protective effects mediated via the receptor. The A3AR has also been identified as a
biological marker to predict a patient‘s eligibility for treatment with the agonists. Taken
together, the utilization of A3AR as both a biological predictive marker and a therapeutic
target encompass the a ‘personalized medicine’ approach and make A3AR agonists
promising small molecule drug candidates.
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Figure 1.
Signaling pathways involved in the action of A3AR agonists. Pathways proposed to be
involved in anticancer, antiinflammatory, and cardioprotective effects of A3AR agonists.
A3AR signals through both G protein-dependent (via Gi or β,γ subunits) and independent
pathways. Translocation of arrestin to the A3AR would be associated with receptor
downregulation [22] and G protein-independent signaling. Not all pathways are present in
all circumstances, and other pathways not shown can also affect cell survival, proliferation,
and differentiation. In cancer (blue arrows), activation of the A3AR corrects an imbalance in
the downstream Wnt signaling pathway [6,34]. Administration of an A3 agonist to activate
its cell surface receptor inhibits the formation of cAMP and indirectly decreases
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phosphorylation (and therefore decreased inactivation) of the serine/threonine kinase
GSK-3β. The resulting increased phosphorylation of β-catenin causes it to be removed from
the cytoplasm by ubiquitination and therefore preventing its nuclear import. This results in a
net suppression of cyclin D1 and c-myc, which leads to cell growth inhibition. With respect
to cancer, NF-κB is a potent anti-apoptotic agent in malignant cells and its activation is
strongly associated with tumors [76]. Additionally, as a major cell survival signal, NF-κB is
involved in multiple steps in carcinogenesis and in cancer cells‘ resistance to chemo- and
radiotherapy. Thus, drugs aimed to decrease expression or activity of NF-κB could abrogate
its anti-apoptotic effect. In inflammatory models [7,8,9,20,29,71], the reduced activation of
NF-κB (in synoviocytes, neutrophils, and other immune cells) has an antiinflammatory
effect, in part by reducing the expression of TNF-α. Opposite effects of A3AR activation on
some of these pathways (green arrows) are associated with myeloprotective (via increased
NF-κB in splenocytes [39]) and cardioprotective (GSK-3β inhibition [47]) responses to
A3AR agonists. In the heart, there are opposing effects of GSK-3β at different stages of
prolonged ischemia (GSK-3β protects) and reperfusion (GSK-3β inhibition protects) [77].
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Figure 2.
Representative agonists (1 – 8) and partial agonists (9, 10) of nanomolar affinity at the
A3AR and a positive allosteric modulator 11. Nucleosides 7 – 10 contain the (North)
methanocarba substitution of the ribose ring, which maintains an A3AR-preferred
conformation.
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Table 1
Effects of A3AR agonists on growth of solid tumors in experimental animal models.
Inflammatory Condition Experimental animal model Refs.
Rheumatoid arthritis Adjuvant & collagen-induced arthritis [7, 38, 68–70]
Osteoarthritis Monosodium iodoacetate-induced osteoarthritis [71]
Inflammatory bowel diseases Dextran sodium sulphate or 2,4,6-trinitrobenzene sulfonic acid-induced colitis; Spontaneous
colitis in interleukin-10 gene deficient mice
[26, 37. 72]
Uveitis IRBP induced Experimental autoimmune uveitis [73]
Sepsis/toxemia CLP and LPS-induced sepsis [35,74]
Pulmonary inflammation LPS inhalation [27]
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Table 2
Effects of A3AR agonists in experimental animal models of inflammatory disease.
Tumor Type Animal strain, Cell line Experimental model Refs.
Melanoma
Mice; B16-F10
Syngeneic; Metastatic
Syngeneic; subcutaneous
[33, 62, 63]
Prostate cancer Rat; AT6.1
Mice; PC3
Xenograft; Metastatic
Xenograft, subcutaneous
[32, 64]
Colon carcinoma Mice; HCT-116
Mice; CT-26
Xenograft, subcutaneous
Syngeneic; Metastatic
[34, 65, 66]
Breast cancer Mice; SK-BR-3 Xenograft, subcutaneous [75]
Hepatocellular carcinoma Rat; N1S1
Mice; Hep3B
Syngeneic; Orthotopic
Xenograft, subcutaneous
[6, 67]
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Table 3
Past and present human clinical studies utilizing CF101 and CF102.
Disease Phase Primary endpoints Refs. Current
status
Rheumatoid arthritis 2a ACR20 response at week 12 [56] Phase 2b
Psoriasis 2 Reduction in PASI score of at least 75% from Baseline (PASI 75) to the end of
the 12 weeks treatment period
[57] Phase 2/3
Dry eye syndrome 2 Improvement of 25% or more over baseline at week 12 in tear film BUT or in
superficial punctate keratitis as assessed by either FS or ST1 results
[60] Phase 3
Hepatocellular carcinoma 1/2 To determine the safety, tolerability, dose-limiting toxicities, maximum tolerated
dose, recommended Phase 2 dose and to assess the repeat-dose pharmacokinetic
behavior of orally administered CF102
Ongoing
Hepatitis C virus infection 1/2 To determine the safety and tolerability of 15 days of orally administered CF102
in patients with chronic hepatitis C genotype 1, to assess the effects on HCV load
during 24 weeks and to assess the repeat-dose pharmacokinetic behavior of
CF102
Ongoing
FS = fluorescein staining ST1 = Schirmer shear test 1
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